Literature DB >> 220278

Cyproheptadine treatment of Nelson's syndrome: restoration of plasma ACTH circadian periodicity and reversal of response to TRF.

D T Krieger, E M Condon.   

Abstract

Administration of cyproheptadine for four months to a patient with Nelson's Syndrome was associated with evidence of skin lightening, decreased plasma ACTH concentrations, return of a normal circadian periodicity of plasma ACTH concentrations, and lack of responsiveness of plasma ACTH concentrations to TRF administration, in contrast to the response seen in the untreated state.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 220278     DOI: 10.1210/jcem-46-2-349

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Effect of cyproheptadine on neuronal ultrastructure in the arcuate nucleus of the rat hypothalamus.

Authors:  I I Drozdovich; V M Gordienko
Journal:  Neurosci Behav Physiol       Date:  1985 Sep-Oct

2.  Cyproheptadine treatment in Cushing's disease.

Authors:  R Tanakol; F Alagöl; H Azizlerli; O Sandalci; T Terzioğlu; F Berker
Journal:  J Endocrinol Invest       Date:  1996-04       Impact factor: 4.256

3.  Thyrotropin-releasing hormone stimulation of adrenocorticotropin production by mouse pituitary tumor cells in culture: possible model for anomalous release of adrenocorticotropin by thyrotropin-releasing hormone in some patients with Cushing's disease and Nelson's syndrome.

Authors:  M C Gershengorn; C O Arevalo; E Geras; M J Rebecchi
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

4.  Suppression of the immune response by drugs interfering with the metabolism of serotonin.

Authors:  M Boranić; D Pericić; M Poljak-Blazi; V Sverko
Journal:  Experientia       Date:  1984-10-15

5.  Direct effects of thyrotropin-releasing hormone, cyproheptadine, and dopamine on adrenocorticotropin secretion from human corticotroph adenoma cells in vitro.

Authors:  M Ishibashi; T Yamaji
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.